Our group developed CATCR-T cells, an antigen-specific cellular therapy platform for the selective targeting of autoreactive B cells. CATCRs are re-engineered T cell receptors that reprogram T cells to eliminate self-reactive B cells while preserving normal immune cells.

BaiTEs are an “off-the-shelf” precision immunotherapy platform for the selective depletion of autoreactive B cells, combining the potency of T cell-engaging therapies with antigen-specific targeting.

IGHV4-34-targeted chimeric TCR-T cells, CAR-T cells, and bispecific T cell engagers are precision immunotherapies for the selective elimination of 9G4 idiotope B cells in lupus, cold agglutinin disease, and lymphoma.

TRBV9-targeted bispecific T cell engaging antibodies are a precision immunotherapy for the selective elimination of autoreactive T cells in ankylosing spondylitis and celiac disease.